Please select the option that best describes you:

Topics: Lung Cancer • Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer

Which patients with metastatic NSCLC with an EGFR mutation would you treat with chemotherapy & osimertinib or amivantamab & lazertinib, and how would you choose between the two regimens?